Dobson backed NICE ruling on flu drugBMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7216.1024 (Published 16 October 1999) Cite this as: BMJ 1999;319:1024
- Gavin Yamey
The former secretary of state for health, Frank Dobson, has backed the National Institute for Clinical Excellence (NICE) in its ruling against the novel influenza drug zanamivir (Relenza).
The institute believes that the current evidence from clinical trials by the manufacturer, Glaxo-Wellcome, suggests only a moderate benefit of the drug to otherwise healthy individuals. The drug reduces flu symptoms by about one day, and the costs of achieving this benefit are uncertain. In the absence of clear evidence of its effectiveness in high risk …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial